Story perspectives

Cigna Cuts Drug Rebates; Organon CEO Resigns Amid Scandal

10/27/2025

28 5

Summary

Story summary

Cigna Group will eliminate prescription drug rebates in many commercial plans by 2027 and replace them with up-front discounts to reduce costs, a move responding to market pressures and aimed at transparency.
Organon CEO Kevin Ali resigned after an internal investigation found improper Nexplanon sales practices, including encouraging wholesalers to purchase excess product.
Organon will implement remedial actions to improve financial controls and will not restate prior statements.

1 of 1

Story summary

Cigna Group will eliminate prescription drug rebates in many commercial plans by 2027 and replace them with up-front discounts to reduce costs, a move responding to market pressures and aimed at transparency.
Organon CEO Kevin Ali resigned after an internal investigation found improper Nexplanon sales practices, including encouraging wholesalers to purchase excess product.
Organon will implement remedial actions to improve financial controls and will not restate prior statements.